HistoWiz, Inc.

HistoWiz, Inc. is a provider of automated histopathology services, transforming tissue specimens into high-quality digital slides for analysis, thereby enhancing efficiency in scientific research and discovery. Founded in 2013, HistoWiz, Inc. is based in Brooklyn, US.

The company specializes in automated histopathology services. It successfully completed a Series A funding round in October 2021, raising USD 32. 00 mn, led by Vivo Capital with contributions from Asahi Kasei Corporation and VenBio Partners. The company has executed a total of 2 deals, with its most recent deal occurring on October 19, 2021.

The CEO and founder, Ke Cheng, has previously established other companies. HistoWiz specializes in automated histopathology services, primarily focusing on transforming tissue specimens into high-quality digital slides for analysis. Their core offerings include GLP-compliant and non-GLP services, advanced immunohistochemistry (IHC) and immunofluorescence (IF) staining with over 400 validated antibodies, and high-throughput scanning for digitizing glass slide collections. The company serves researchers and institutions in the life sciences sector, with an emphasis on accelerating scientific research and discovery through efficient digital pathology solutions.

HistoWiz operates primarily in North America, with an expanding presence in Europe and Asia, catering to a diverse clientele that includes academic institutions, pharmaceutical companies, and biotechnology firms. HistoWiz generates revenue through a transactional model centered on service-based offerings, including histology and digital pathology solutions. Clients place orders for tissue processing, slide generation, and image analysis, following a streamlined workflow that integrates sample submission and digital result access. Pricing structures for specific services, such as advanced IHC and IF staining, are established based on the complexity and volume of the requested analyses.

The company focuses on B2B transactions, engaging directly with research institutions and laboratories to meet their histopathology needs, thereby fostering long-term partnerships that enhance their service delivery and client satisfaction. In October 2021, HistoWiz, Inc. raised USD 32. 00 mn in Series A funding, which will be utilized to expand its services and build a flagship lab featuring the latest tissue-sectioning and embedding robots.

The company plans to grow its team to better serve clients and continue innovating within the field of histopathology. HistoWiz aims to enhance its presence in the European and Asian markets, aligning these efforts with the anticipated advancements driven by the recent funding.